Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Original) 2- $(\alpha$ -n-pentanonyl)benzoates having the following formula

wherein n is 1 or 2; M is a monovalent metal ion, a bivalent metal ion or an organic base group.

2. (Previously Presented) The 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is a monovalent metal ion selected from the group consisting of Li⁺, Na⁺ and K⁺.

Claims 3-10. (Cancelled)

- 11. (Previously Presented) The 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is a bivalent metal ion selected from the group consisting of Mg²⁺, Ca²⁺ and Zn²⁺.
- 12. (Previously Presented) The 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is an organic base group selected from the group consisting of benzyl amine, t-butyl amine, methyl benzyl amine and N,N'-dibenzylethylenediamine.
- 13. (Previously Presented) The 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is selected from the group consisting of Na⁺, K⁺, Ca²⁺, and N,N'-dibenzylethylenediamine.

Appl. No. 10/598,826 Amdt. dated January 11, 2007 Preliminary Amendment

- 14. (Previously Presented) A method for preparing the 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is an organic base group, said method comprises:
 - hydrolyzing 3-n-butenylphthalide under an alkaline condition;
 - acidifying the hydrolyzed product to obtain 2-(α -n-pentanonyl)benzoic acid;
 - dissolving the 2-(α -n-pentanonyl)benzoic acid in a solvent with low polarity and then reacting with an organic base to form a salt; and
 - separating out the salt.
- 15. (Previously Presented) The method of claim 14, wherein the solvent with low polarity comprises benzenes, ethers, dichloromethane, and ethyl acetate.
- 16. (Currently Amended) The method of claim 14, wherein M is selected from the group consisting of Na⁺, K⁺, Ca²⁺, and N,N'-dibenzylethylenediamine wherein M is an organic base group selected from the group consisting of benzyl amine, t-butyl amine, methyl benzyl amine and N,N'-dibenzylethylenediamine.
- 17. (Previously Presented) A method for preparing the 2-(α-n-pentanonyl)benzoates of claim 1, wherein M is a monovalent metal ion, said method comprises:
 - hydrolyzing 3-n-butenylphthalide under an alkaline condition;
 - acidifying the hydrolyzed product to obtain 2-(α -n-pentanonyl)benzoic acid;
 - reacting the 2-(α -n-pentanonyl)benzoic acid with a metal ionic base dissolved in a solvent with high polarity to form a salt, and then adding a solvent with low polarity under stirring; and
 - separating out the salt.
- 18. (Previously Presented) The method of claim 17, wherein the solvent with high polarity comprises C1-C4 lower alcohols, and wherein the solvent with low polarity comprises benzenes, ethers, dichloromethane, and ethyl acetate.

Appl. No. 10/598,826 Amdt. dated January 11, 2007 Preliminary Amendment

- 19. (Previously Presented) The method of claim 17, wherein M is a monovalent metal ion selected from the group consisting of Li⁺, Na⁺ and K⁺.
- 20. (Previously Presented) The method of 14, wherein the solvent with low polarity is ethyl ether.
- 21. (Previously Presented) The method of claim 17, wherein the solvent with low polarity is ethyl ether, and the solvent with high polarity is methanol.
- 22. (Previously Presented) A method for preparing the 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is a bivalent metal ion, said method comprising mixing a solution of 2-(α -n-pentanonyl)benzoates with a solution of bivalent metal ion salt, performing trans-salification to obtain 2-(α -n-pentanonyl)benzoates of bivalent metal ion.
- 23. (Previously Presented) The method as claimed in claim 22, wherein M is a bivalent metal ion selected from the group consisting of Mg²⁺, Ca²⁺ and Zn²⁺.
- 24. (Previously Presented) A method for treating or preventing cardio-cerebral ischemic diseases, alleviating the disturbance of cardio-cerebral circulation and inhibiting thrombosis in a subject, comprising administering to a subject a therapeutically effective amount of the 2-(α -n-pentanonyl)benzoates of claim 1.
- 25. (Previously Presented) A pharmaceutical composition for treating or preventing cardio-cerebral ischemic diseases, alleviating the disturbance of cardio-cerebral circulation and inhibiting thrombosis, comprising a therapeutically effective amount of the 2-(α -n-pentanonyl)benzoates of claim 1, and one or more pharmaceutically acceptable carriers.
- 26. (Previously Presented) The pharmaceutical composition of claim 25, which is formulated into tablets, capsules, granules, intravenous injections, or lyophilized intravenous injections.